Indian pharmaceutical companies are poised to benefit from a major global patent expiry cycle, with drugs generating nearly $142 billion in sales in CY25 set to lose exclusivity between 2026 and 2030, according to a report by CareEdge Ratings. The report estimates that the upcoming patent cliff could create a market opportunity of over $30-40 […]